The α1 adrenoceptor antagonist tamsulosin for the treatment of voiding symptoms improves nocturia and sleep quality in women.
Nocturia is the main cause of disturbance of sleep maintenance and negatively impacts quality of life (QoL). We assessed the effects of the α1-adrenoceptor antagonist, tamsulosin, on nocturia and quality of sleep, for the treatment of lower urinary tract symptoms (LUTS) in women with a maximal flow rate (Qmax) less than 15 mL/sec. From January 2008 to December 2009, women with LUTS [Qmax ≤ 15 mL/s, International Prostate Symptom Score (IPSS) ≥ 8] and nocturia (void/night ≥ 1) were selected for this study. Two hundred ninety six patients completed voiding diary, a questionnaire on the Medical Outcomes Study (MOS) sleep scale and underwent follow-up evaluation after 4 weeks of treatment (tamsulosin, 0.2 mg, once daily). Effectiveness was assessed by analysis of the IPSS, the bother score, the Qmax, and postvoid residual urine (PVR). The mean number of voids per night was 2.66 ± 1.3, and the total IPSS and bother scores were 15.2 ± 8.9 and 3.4 ± 1.2, respectively. Clinical parameters, including the IPSS, the bother score, the Qmax and the PVR, improved significantly from baseline after treatment (P < .05). The change in nocturia was -1.12 (P < .05). Concerning sleep quality, the sleep problem index showed a significant decrease. Among the items on the sleep subscale, sleep disturbance, somnolence, and sleep adequacy were significantly changed (P < .05). The α1-adrenoceptor antagonist tamsulosin significantly improved nocturia and sleep quality as well as LUTS in women with low Qmax.